ChroMedX Announces Operations Update and Advisory Board Appointment
(firmenpresse) - ChroMedX Announces Operations Update and Advisory Board Appointment
October 28, 2014 - ChroMedX Corp. (the Company) (CSE: CHX, OTC: MNLIF, Frankfurt: EIY2), a developer of in vitro diagnostics and point-of-care technologies is pleased to provide a HemoPalm development update and announce Dr. Cynthia Balion as the first appointment to the Companys Technical Advisory Board.
Dr. Wayne Maddever, P.Eng., Chief Executive Officer of ChroMedX Corp. is pleased to provide the following update on the Companys HemoPalm development programme and addition to ChroMedXs Technical Advisory Board.
Led by ALine Inc., HemoPalm development has progressed as planned and continues to be on target for completion of the prototype in Q1, 2015. Key components have been received including calibration fluid pouches manufactured in Germany, which are essential for biosensor calibration and stability testing of the contents of the calibration pouches has commenced in Ontario, Canada. Other key components including microspectrometers, have been ordered and delivery is expected within the next 2-3 weeks. Testing of the microspectrometers will be performed jointly between ALine in Rancho Domingo, CA., and Ontario, Canada
We are very pleased to welcome Dr. Cynthia Balion, Associate Professor of Pathology and Molecular Medicine, McMaster University as the initial member of the Companys Technical Advisory Board.
Dr. Balion is also a clinical biochemist for the Hamilton Regional Laboratory Medicine Program (HRLMP) and co-investigator for the Canadian Longitudinal Study on Aging (CLSA) where she is the director of the Biorepository and Bioanalysis Centre.
The CLSA is a large, national, long-term study that follows 50,000 men and women between the ages of 45 and 85 for 20 years. As the most comprehensive study of health and aging in Canada, the CLSA collects information on the changing biological, medical, psychological, social, lifestyle and economic aspects of peoples lives as they age.
About ChroMedX Corp.
ChroMedX Corp. is a medical technology company focused on the development of novel medical devices for in vitro diagnostics and point-of-care testing. The devices are protected by the Companys issued US and pending international patents, dealing with blood collection, analysis and plasma/serum processing.
Follow ChroMedX Corp.:
Website: www.ChroMedX.comFacebook: facebook.com/ChroMedXcorpTwitter: www.twitter.com/ChroMedXcorp
Contact
Wayne MaddeverPresident, CEO & Director647-872-9982
W. Clark KentCorporate Development647-519-2646ckent(at)ChroMedX.com
CHROMEDX CORP
Suite 520 - 65 Queen Street West Toronto, Ontario M5H 2M5
Büro: 647-872-9982
Tel (gebührenfrei)/Fax: 1-844-247-6633
E-Mail: info(at)ChroMedX.com
CSE:CHX - OTC: MNLIF
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Forward-looking Information Cautionary Statement
Except for statements of historic fact, this news release contains certain "forward-looking information" within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements are based on the opinions and estimates at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements including, but not limited to delays or uncertainties with regulatory approvals, including that of the CSE. There are uncertainties inherent in forward-looking information, including factors beyond the Companys control. The Company undertakes no obligation to update forward-looking information if circumstances or management's estimates or opinions should change except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements. Additional information identifying risks and uncertainties that could affect financial results is contained in the Companys filings with Canadian securities regulators, which filings are available at www.sedar.com
Leseranfragen:
ChroMedX Corp. ist ein Medizintechnikunternehmen, das auf die Entwicklung neuartiger medizinischer Geräte für die In-vitro-Diagnostik und Point-of-Care-Untersuchungen spezialisiert ist. Die Geräte sind durch die in den USA erteilten und auf globaler Ebene schwebenden Patente, die die Blutentnahme und –untersuchung sowie die Plasma-/Blutserumverarbeitung betreffen, geschützt.
Datum: 28.10.2014 - 09:55 Uhr
Sprache: Deutsch
News-ID 347319
Anzahl Zeichen: 4772
contact information:
Town:
Wien
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 172 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"ChroMedX Announces Operations Update and Advisory Board Appointment
"
steht unter der journalistisch-redaktionellen Verantwortung von
ChroMedX Corp. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
